U.S. High Court To Hear Fosamax Preemption Case Jan. 7; Solicitor General Included

(December 3, 2018, 12:52 PM EST) -- WASHINGTON, D.C. — Arguments about whether the Food and Drug Administration rejected a stronger warning about leg fractures on the label of the osteoporosis drug Fosamax will be heard by the...

To view the full article, register now.